this paper is based on a longer report on the benefits safety and modalities of information representation with regard to women and statin use situated within the historical context of womens health movement which has advocated for unbiased appropriate medical research and prescribing for women based on the goals of fulldisclosure informed consent evidencebased medicine and genderbased analysisthe evidence base for prescribing statins for women especially for primary prevention is weak yet canadian data suggest that half of all prescriptions are for womensafety metaanalyses do not disaggregate for women do not consider female vulnerability to statin induced muscle problems and womencentred concerns such as breastcancer miscarriage or birth defects are underresearchedmany trials have not published their noncardiac serious adverse event datathese factors suggest that the standards of fulldisclosure informed consent evidencebased prescribing and genderbased analysis are not being met and women should proceed with caution